REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) > Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same > Disclosed Amino Acid Sequence Derived From Virus Disclosed Amino Acid Sequence Derived From VirusDisclosed Amino Acid Sequence Derived From Virus patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/19/07 - 20070166319 - Human papilloma virus immunoreactive peptides This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides. ... 06/21/07 - 20070141074 - Agents for the inhibition of virus replication through regulation of protein folding The invention concerns agents for the treatment of acute and chronic infections with human and animal pathogenic viruses which assemble along the cell membrane and are released through budding on the surface of the cell. Hereunto count especially causative agents of infectious diseases such as AIDS, hepatitis, hemorrhagic fever, SARS, ... 06/14/07 - 20070134262 - Antigens encoded by alternative reading frames from pathogenic viruses The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids. ... 05/31/07 - 20070122424 - Peptide-based vaccine for influenza A human synthetic peptide-based influenza vaccine for intranasal administration comprises a mixture of flagella containing at least four epitopes of influenza virus reactive with human cells, each expressed individually in Salmonella flagellin, said influenza virus epitopes being selected from the group consisting of: (i) one B-cell hemagglutinin (HA) epitope; (ii) ... 03/08/07 - 20070053922 - Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and ... 03/01/07 - 20070048329 - Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor Immunogenic cytotoxic T cell epitope peptides of Epstein Barr Virus LMP1 protein are provided having between nine and seventeen amino acids and minimal consensus sequences selected from QRH, AGNDG, QNW, VLYS and DSNSNE. These peptides, either individually or in polyepitope constructs, are useful in pharmaceutical compositions, vaccines and methods of ... 02/22/07 - 20070041990 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 02/22/07 - 20070041989 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 02/22/07 - 20070041988 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, ... 02/01/07 - 20070026009 - Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. ... 01/18/07 - 20070014810 - Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and ... 01/04/07 - 20070003566 - Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated ... 01/04/07 - 20070003565 - Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist The present invention relates to use of HAb18G/CD147 molecule as target for designing antiviral antagonist and the antiviral antagonist designed by using such molecule, especially antagonist against SARS Coronavirus and AIDS virus HIV-1. Antagonist of the present invention includes antibody, polypeptide, immune complex, derivative, small molecule compound and so on, ... 12/14/06 - 20060280752 - Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases Described herein are peptide epitopes effective in the treatment of herpes simplex virus (HSV), as well as vaccines and other therapeutic compositions including the same. In various embodiments, the compositions of the present invention may include a pharmaceutically acceptable adjuvant to enhance the delivery and/or pharmacological efficacy of the epitope. ... 11/02/06 - 20060246087 - Hetero type pentamer recombinant vaccine A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A ... 10/19/06 - 20060233821 - Compositions and methods for the inhibition of membrane fusion by paramyxoviruses Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a ... 10/19/06 - 20060233820 - Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the ... 10/05/06 - 20060222659 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 10/05/06 - 20060222658 - Vaccinia virus nucleic acids, polypeptides and immunogenic compositions The present invention provides transcriptionally active vaccinia virus polynucleotides, recombinant vaccinia virus polypeptides, and immunogenic vaccinia virus antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. ... 10/05/06 - 20060222657 - Polypeptide transduction and fusogenic peptides Due to the barrier imposed by the cell membrane, delivery of macromolecules in excess of 500 Daltons directly into cells remains problematic. However, proteins, which have been evolutionarily selected to perform specific functions, are therefore an attractive therapeutic agent to treat a variety of human diseases. In practice, the direct ... 09/28/06 - 20060216304 - Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for ... 08/03/06 - 20060171955 - Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least a 5-fold increase in F and G protein yields when compared with the parent A2 ... 07/27/06 - 20060165714 - Peptides for vaccination against human cmv The present invention relates to peptides or pretide derivatives of the 65 kD lower matrix phosphoprotein of human cytomegalovirus. The peptides disclosed are useful for determining whether subjects have een exposed to human cytomegalovirus. Methods for using these peptides or derivatives thereof to determine the peptide-induced production of interferon-γ and/or ... 07/27/06 - 20060165713 - Vaccine The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections. In particular the invention relates to nucleic acid molecules encoding E1 and/or E2 and vectors suitable for DNA vaccine delivery, and pharmaceutical compositions containing them. Methods for manufacturing said molecules, vectors ... 07/20/06 - 20060159696 - Neutralizing epitope-based growth enhancing vaccine The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided. ... 07/20/06 - 20060159695 - Anti-respiratory syncytial virus antibodies, antigens and uses thereof Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed. ... 07/13/06 - 20060153864 - Papilloma virus-like particles, fusion proteins as well as processes for their production The invention relates to the recombinant production of proteins as well as VLPs which are suitable as a vaccine for therapeutic and prophylactic vaccination. The invention also relates to processes for the production and purification of recombinant papilloma virus proteins and fusion proteins. ... 07/13/06 - 20060153863 - Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory iga's A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine ... 07/13/06 - 20060153862 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated ... 06/08/06 - 20060121048 - Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof The present invention provides genetically engineered cell lines, recombinant vectors, and vaccines. The present invention also provides methods for generating an in vitro system for Varicella zoster virus (VZV), and the in vitro systems generated by these methods. The present invention further provides methods for reactivating VZV, and VZV reactivated ... 06/01/06 - 20060115488 - Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV ... 05/11/06 - 20060099220 - Antibodies against and methods for producing vaccines for respiratory syncytial virus The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The ... 05/11/06 - 20060099219 - Mutated hpv-16e7 polypeptide, pharmaceutical composition comprising it and its preparation process The present invention is related to a mutated E7 polypeptide obtained from the human Papillomavirus HPV-16 as well as the pharmaceutical composition comprising it and its preparation process. ... 05/04/06 - 20060093616 - Process for vaccinating eucaryotic hosts and for protecting against sars-cov infection The present invention relates to a process for vaccinating humans and for protecting against SARS-CoV infection. ... 04/06/06 - 20060073160 - Cloning of chicken anemia virus dna Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (“CAV”)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained. ... 03/23/06 - 20060062800 - Compositions, methods and kits relating to poxvirus subunit vaccines The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as ... 02/23/06 - 20060039919 - Fusion protein for inhibiting cervical cancer A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide ... 02/16/06 - 20060034859 - Naturally processed measles virus peptides eluted from class ii hla molecules A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more ... 02/09/06 - 20060029612 - Prevention and treatment of recurrent respiratory papillomatosis Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes. ... 02/02/06 - 20060024320 - Attenuated pestiviruses This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these. ... 02/02/06 - 20060024319 - Murine calicivirus The invention disclosed herein relates to a newly discovered murine norovirus, and compositions and methods related thereto. ... 01/19/06 - 20060013824 - Rsv proteins, antibodies, compositions, methods and uses The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. ... 01/05/06 - 20060002952 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in ... 01/05/06 - 20060002951 - Inhibition of the trnalys3-primed initiation of reverse transcription in hiv-1 by apobec3g The present invention generally relates to the field of antiviral therapy. More specifically, the present invention relates to the inhibition of the tRNALys3-primed initiation of reverse transcription in viruses by APOBEC3G. The present invention further relates to a method of treating or preventing viral infections by inhibiting tRNALys3 annealing and/or ... 12/29/05 - 20050287161 - Vaccine This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV16 and HPV 18 virus like particles provides cross-protection against other HPV types. ... 12/08/05 - 20050271677 - Flavivirus fusion inhibitors The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The ... 11/24/05 - 20050260220 - Recombinant therapeutic fusion proteins A recombinant bifunctional fusion protein comprises a first component which is the antigenic ectodomain of measles virus hemagglutinin protein (MeaH) genetically modified not to bind to human cells; and a second component fused thereto which is capable of binding to the surface structure of genetically variable viruses such as HCV ... 11/17/05 - 20050255123 - Chimeric ebola virus envelopes and uses therefor Chimeric ebola envelope proteins and uses therefore are described. The chimeric envelope proteins are useful for packaging viral vectors and targeting these vectors in vivo, to lung cells following intratracheal delivery or for delivery of molecules, ex vivo, to macrophages and dendritic cells. In another aspect, also provided herein are ... 11/10/05 - 20050249745 - Papilloma virus truncated l1 protein and fusion protein constructs Vaccine formulations comprising, viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed. ... 11/10/05 - 20050249744 - Mhc class ii haplotype specific immunodominancy of peptides derived from rsv fusion (f) and attachement (g) proteins The present invention relates immunodominant peptides derived from human respiratory syncytial virus (H-RSV) that may be used in ex vivo diagnosis of immune responses to H-RSV The immunodominant peptides are derived from the H-RSV Fusion (F) and Attachment (G) proteins and are capable of inducing an antigen specific CD4+ T ... 11/03/05 - 20050244423 - Methods for treating viral infection using il-28 and il-29 cysteine mutants IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 10/20/05 - 20050232933 - Cmv-ie1 peptides and method of use IE1 peptide antigens that are recognized by and stimulate production of CMV-specific cytotoxic T lymphocytes are useful for vaccines, in the form of peptides, DNA vaccines or cellular vaccines, and also for diagnostic methods. ... 10/13/05 - 20050226889 - Inhibition of viral infection and spread with viral and rhoa-derived peptides Isolated peptides, peptidomimetics, and antibodies which bind to the viral fusion protein binding domain of the RhoA protein or the RhoA binding domain of a viral fusion protein are useful for inhibiting infection in susceptible cells, in vitro and in vivo. Among these viruses are the Paramyxovirus respiratory syncytial virus ... 09/29/05 - 20050214316 - Methods of characterizing infectious bursal disease virus Characterization of infectious bursal disease virus (“IBDV”) for use in vaccine identification and production that provides rapid selection of a specific vaccine strain with an IBDV sequence most related to the IBDV of interest or identification of a novel strain of IBDV. ... 09/22/05 - 20050208066 - Recombinant baculovirus and virus-like particle Recombinant baculoviruses, virus-like particles, and polypeptide that contain a protein sequence of a heterologous virus, related compositions, and related preparation, screening, delivery, detection, and treatment methods. ... 07/28/05 - 20050163795 - Ihnv g protein for immune stimulation A vaccine comprises a portion of IHNV G protein and a portion of a second protein from a fish pathogen, or their respective nucleic acid coding sequences. The presence of the IHNV G protein boosts the immune response to the second protein, resulting in a protective effect against infection by ... 07/28/05 - 20050163794 - Immunological herpes simplex virus antigens and methods for use thereof The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity ... 06/23/05 - 20050136067 - Chimeric immunogens Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory ... 06/16/05 - 20050129704 - Plant-derived vaccines against respiratory syncytial virus A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are ... 06/16/05 - 20050129703 - Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola ... ### FreshPatents.com Support - Terms & Conditions |